Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
Trial details
- Registry ID
- NCT04551911
- Phase
- Phase 2
The FDA approved Rayaldee (CTAP101 Capsule) on 17 Jun 2016.
Drug identity checked against registry records
Also recorded as CTAP101 Capsule
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19NCT04551911 | OPK | Phase 2 | Completed | 2021-10-08Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2016-06-17Day | Rayaldee | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA208010", "applicant_as_listed_by_fda": "EIRGEN", "brand_names": ["RAYALDEE"], "active_ingredients": ["CALCIFEDIOL"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20160617", "matched_on": "drug name equals FDA brand name"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |